



## CONSULTATION OF THE NOTEHOLDERS IN THE CONTEXT OF THE CONTEMPLATED INITIAL PUBLIC OFFERING OF ICADE SANTÉ

On 7 June 2021, Icade SA, the majority shareholder of Icade Santé holding 58.30% of its share capital, announced its intention to have Icade Santé's shares admitted to trading on the regulated market of Euronext Paris by the end of 2021 (the "**Contemplated IPO**"), subject to market conditions, in order to finance its ambitious development and investment plan.

For the purposes of the Contemplated IPO, Icade Santé will be required, in accordance with applicable regulations, to change its corporate form from a société par actions simplifiée to a société anonyme à conseil d'administration before its shares can be admitted to trading on the regulated market of Euronext Paris.

In addition, in the context of the Contemplated IPO, it is envisaged to regroup the international activities of Icade SA's healthcare property investment activities within Icade Santé, which are currently carried out by Icade Healthcare Europe, a subsidiary of Icade SA, which will require to extend the current corporate purpose of Icade Santé (which is currently limited to France), to international activities.

In this context, the holders of the EUR 500 000 000 notes issued on 4 November 2019 by Icade Santé bearing interest at a rate of 0.875 per cent and maturing on 4 November 2029 – ISIN : FR0013457967 (the "**Notes**") were convened in a general meeting on 27 July 2021 on first convocation and, if the quorum is not reached, on 2 August 2021 on second convocation, in particular with a view to approve the change of Icade Santé's corporate form from a *société par actions simplifiée* to a *société anonyme à conseil d'administration* and also to approve certain modifications of Icade Santé's corporate purpose, including the extension of its activities (which are currently limited to France) to international activities. The change of corporate form and the abovementioned amendments to the by-laws would enter into force from the date of approval by the French Autorité des marchés financiers of the prospectus relating to the admission of Icade Santé's shares to trading on the regulated market of Euronext Paris.

Icade Santé invites the holders of the Notes to consult the section dedicated to the general meeting of the holders of Notes on the company's website ([www.icode-sante.fr](http://www.icode-sante.fr)).

### *Disclaimer*

*This press release does not contain and does not constitute an offer to sell securities, or an invitation or the solicitation to invest in securities in France, in the United States or in any other jurisdiction.*

---

### ABOUT ICADE SANTÉ

With a portfolio worth €5.2 billion (on a full consolidation basis) as of December 31, 2020, Icade Santé is the leading investor in private healthcare facilities in France. A 58.3% owned subsidiary of the Icade Group, Icade Santé draws on its proven expertise, its long-term shareholders as well as its extensive knowledge of the real estate value chain. Since 2017, Icade Santé has pursued a strategy of diversification into the nursing home segment.

Icade and Icade Santé are rated BBB+ with a stable outlook by rating agency S&P.

The text of this press release is available on the Icade Santé website: <https://icode-sante.fr>

### CONTACTS

Yoann Nguyen  
Head of Investors Relations  
+33(0)6 31 58 97 31  
[yoann.nguyen@icode.fr](mailto:yoann.nguyen@icode.fr)

Etienne Maurer  
Deputy CFO  
+33(0)1 41 57 79 02  
[etienne.maurer@icode.fr](mailto:etienne.maurer@icode.fr)